Your cart is currently empty!
Pentaglobin (Human Normal Immunoglobulin) Injection
Generic brands for Human Normal Immunoglobulin Injection Available in India Brand Name Pentaglobin Generic Name Human Normal Immunoglobulin Strength 0.5g, 2.5g, 5g, 10g, and 16.5% Manufacturer Paviour Pharmaceuticals Pvt. Ltd
Description
Description
This page contains brief details about the drug human normal immunoglobulin, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Date of Approval
Human Normal Immunoglobulin is an immunomodulatory agent which was approved for its medical use in 1981.
Mechanism of Action of Human Normal Immunoglobulin
Human Normal Immunoglobulin Injection belongs to the class of immunostimulants. Human Normal Immunoglobulin works by restoring the immunoglobulin G (IgG) antibodies. It directly binds to the Fc fragment specific receptors, acts against inflammatory mediators and induces cell death in B cells and T cells, eventually reducing inflammation and reducing the severity of infections.
Uses of Human Normal Immunoglobulin
Human Normal Immunoglobulin Injection has been developed to treat adults with inflammatory disorders, primary and secondary immunodeficiencies.
Human Normal Immunoglobulin Dosage available
Human Normal Immunoglobulin is available as a vial containing solution for injection, intended for administration as an intravenous infusion. It is available in the doses 0.5g, 2.5g, 5g, 10g, and 16.5%. The dosing and frequency vary according to the medical condition and bodyweight.
We can ship to :
News/Updates
References
- Octapharma USA Inc., US Food & Drug Administration, [Revised on Mar 2022] [Accessed on 10th Oct 2022], https://www.fda.gov/media/70911/download
- Octapharma AG, Therapeutic Goods Administration, [Revised on Mar 2021] [Accessed on 10th Oct 2022], https://www.tga.gov.au/sites/default/files/auspar-human-normal-immunoglobulin-210621-pi.pdf
- Novaretti MC, Dinardo CL, Immunoglobulin: production, mechanisms of action and formulations, Rev Bras Hematol Hemoter, 2011, 33(5), 377-82, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415776/pdf/rbhh-33-377.pdf